Schonfeld Strategic Advisors LLC Sells 229,157 Shares of ESSA Pharma Inc. (NASDAQ:EPIX)

Schonfeld Strategic Advisors LLC reduced its position in shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) by 82.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 48,843 shares of the company’s stock after selling 229,157 shares during the quarter. Schonfeld Strategic Advisors LLC owned approximately 0.11% of ESSA Pharma worth $87,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Two Sigma Securities LLC bought a new stake in ESSA Pharma during the 4th quarter valued at $29,000. FNY Investment Advisers LLC bought a new stake in ESSA Pharma during the 4th quarter valued at $44,000. Lepercq Multi Asset Fund bought a new stake in ESSA Pharma during the 4th quarter valued at $54,000. XTX Topco Ltd bought a new stake in ESSA Pharma during the 4th quarter valued at $67,000. Finally, Vazirani Asset Management LLC bought a new stake in ESSA Pharma during the 4th quarter valued at $90,000. 75.12% of the stock is currently owned by institutional investors.

ESSA Pharma Trading Up 3.0%

NASDAQ:EPIX opened at $1.72 on Thursday. The company has a 50-day moving average price of $1.64 and a 200-day moving average price of $1.79. ESSA Pharma Inc. has a 12 month low of $1.40 and a 12 month high of $7.88. The stock has a market cap of $76.35 million, a price-to-earnings ratio of -2.49 and a beta of 1.69.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last posted its earnings results on Thursday, May 8th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.05. Equities analysts forecast that ESSA Pharma Inc. will post -0.42 EPS for the current fiscal year.

ESSA Pharma Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.